{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:31Z","timestamp":1790399851483,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004954","name":"Augustinus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01 DA041336"],"award-info":[{"award-number":["R01 DA041336"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.bcp.2020.113979","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T19:59:57Z","timestamp":1586807997000},"page":"113979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH"],"prefix":"10.1016","volume":"177","author":[{"given":"Anders A.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Halberstadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"M\u00e4rcher-R\u00f8rsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna U.","family":"Odland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Chatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Speth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Liebscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Br\u00e4uner-Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Palner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper T.","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper L.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.113979_b0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bcp.2020.113979_b0010","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195\u2013213","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2020.113979_b0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin G protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0020","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00213-017-4545-5","article-title":"A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment","volume":"234","author":"Palacios","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u2013it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.phrs.2018.09.014","article-title":"Evolutionary considerations on 5-HT2 receptors","volume":"140","author":"Moutkine","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2020.113979_b0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3389\/fphar.2015.00225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0045","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-25761-2_4","article-title":"Serotonergic mechanisms as targets for existing and novel antipsychotics","author":"Meltzer","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pharmthera.2016.10.008","article-title":"New therapeutic opportunities for 5-HT2 receptor ligands","volume":"170","author":"Maroteaux","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0055","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00213-018-5042-1","article-title":"The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug","volume":"235","author":"Jalal","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways","volume":"36","author":"Lopez-Gimenez","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.bcp.2020.113979_b0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bcp.2020.113979_b0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2020.113979_b0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0080","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2020.113979_b0085","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bcp.2020.113979_b0090","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.bcp.2020.113979_b0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0100","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3762\/bjoc.8.194","article-title":"trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family","volume":"8","author":"Pigott","year":"2012","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.bcp.2020.113979_b0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0026-895X(25)09149-7","article-title":"Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus","volume":"50","author":"Almaula","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00005315","article-title":"Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, 5-HT2B and 5-HT2C receptors","volume":"359","author":"Nelson","year":"1999","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.117.239905","article-title":"Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist","volume":"361","author":"Jensen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/cn3000668","article-title":"Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands","volume":"4","author":"Juncosa","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2020.113979_b0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/cn400216u","article-title":"Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A\/2C agonists","volume":"5","author":"Hansen","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2020.113979_b0130","article-title":"DARK classics in chemical neuroscience: NBOMes","author":"Poulie","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bcp.2020.113979_b0135","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36","volume":"34","author":"Ettrup","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bcp.2020.113979_b0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.neuroimage.2016.02.001","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: test-retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin","volume":"130","author":"Ettrup","year":"2016","journal-title":"Neuroimage"},{"key":"10.1016\/j.bcp.2020.113979_b0145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41398-019-0468-8","article-title":"Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans","volume":"9","author":"da Cunha-Bang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bcp.2020.113979_b0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/s41386-019-0567-5","article-title":"Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge","volume":"45","author":"Erritzoe","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fphar.2018.00017","article-title":"Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice","volume":"9","author":"Buchborn","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0160","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2016.03.038","article-title":"Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice","volume":"107","author":"Halberstadt","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0165","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00213-014-3739-3","article-title":"Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice","volume":"232","author":"Fantegrossi","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0170","article-title":"The 5-hydroxytryptamine 2A receptor agonists DOI and 25CN-NBOH decrease marble burying and reverse 8-OH-DPAT-induced deficit in spontaneous alternation","author":"Odland","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0180","doi-asserted-by":"crossref","DOI":"10.1177\/0269881120903465","article-title":"The serotonin 2A receptor agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner","author":"Buchborn","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0185","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1016\/j.bmc.2014.12.011","article-title":"Synthesis and pharmacological evaluation of N-benzyl substituted 4-bromo-2,5-dimethoxyphenethylamines as 5-HT2A\/2C partial agonists","volume":"23","author":"Hansen","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2020.113979_b0190","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/jm301656h","article-title":"Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A\/5-HT2C receptor agonists with pro-cognitive properties","volume":"56","author":"Jensen","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.113979_b0195","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0200","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/mol.117.108605","article-title":"A novel selective inverse agonist of the CB2 receptor as a radiolabeled tool compound for kinetic binding studies","volume":"92","author":"Martella","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.neuropharm.2018.02.028","article-title":"Receptor binding profiles and behavioral pharmacology of ring-substituted N, N-diallyltryptamine analogs","volume":"142","author":"Klein","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","article-title":"Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement","volume":"227","author":"Halberstadt","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0215","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2013.08.025","article-title":"Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response","volume":"77","author":"Halberstadt","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0220","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0022-3565(24)29501-X","article-title":"Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists","volume":"298","author":"Christopoulos","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0225","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/0269881111420313","article-title":"A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments","volume":"26","author":"Clark","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/7854_2016_466","article-title":"Effect of hallucinogens on unconditioned behavior","volume":"36","author":"Halberstadt","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.bcp.2020.113979_b0235","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/dta.1985","article-title":"Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)","volume":"9","author":"Brandt","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.bcp.2020.113979_b0240","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.113979_b0245","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00213-018-5118-y","article-title":"Chronic treatment with a metabotropic mGlu2\/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen","volume":"236","author":"Halberstadt","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0250","first-page":"24","article-title":"Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying","volume":"6","author":"Gyertyan","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-009-1466-y","article-title":"Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety","volume":"204","author":"Thomas","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2006.07.015","article-title":"A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants","volume":"547","author":"Nicolas","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0265","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/mol.114.095265","article-title":"Pharmacological characterization of [3H]VUF11211, a novel radiolabeled small-molecule inverse agonist for the chemokine receptor CXCR3","volume":"87","author":"Scholten","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0270","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00178722","article-title":"[3H]MDL 100,907: a novel selective 5-HT2A receptor ligand","volume":"354","author":"Johnson","year":"1996","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0275","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0028-3908(98)00102-6","article-title":"[3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain","volume":"37","author":"Lopez-Gimenez","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00213-012-2904-9","article-title":"Effects of mood stabilizers on marble-burying behavior in mice: involvement of GABAergic system","volume":"226","author":"Egashira","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0285","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1248\/bpb.35.376","article-title":"Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice","volume":"35","author":"Egashira","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bcp.2020.113979_b0290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1254\/jphs.11228SC","article-title":"N-acetyl-L-cysteine inhibits marble-burying behavior in mice","volume":"119","author":"Egashira","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2020.113979_b0295","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2015.01.001","article-title":"Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action","volume":"1601","author":"Andreasen","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2020.113979_b0300","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/FBP.0000000000000243","article-title":"Positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptors differentially modulates the behavioural effects of citalopram in mouse models of antidepressant and anxiolytic action","volume":"27","author":"Fitzpatrick","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0305","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0310","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1046\/j.1471-4159.1999.0722127.x","article-title":"High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action","volume":"72","author":"Fitzgerald","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2020.113979_b0315","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00213-011-2207-6","article-title":"Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL\/6N mice","volume":"215","author":"Dougherty","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0320","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0026-895X(25)13653-5","article-title":"A single point mutation (Phe340\u2013>Leu340) of a conserved phenylalanine abolishes 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]mesulergine but not [3H]ketanserin binding to 5-hydroxytryptamine2 receptors","volume":"43","author":"Choudhary","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0079-6123(08)00919-9","article-title":"Dopamine\/serotonin releasers as medications for stimulant addictions","volume":"172","author":"Rothman","year":"2008","journal-title":"Prog. Brain Res."},{"issue":"719\u201330","key":"10.1016\/j.bcp.2020.113979_b0330","article-title":"5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology","volume":"172","author":"Peng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.113979_b0335","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1016\/j.bmcl.2005.06.104","article-title":"SAR of psilocybin analogs: discovery of a selective 5-HT2C agonist","volume":"15","author":"Sard","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.113979_b0340","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2020.113979_b0345","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bcp.2020.113979_b0350","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0922-4106(94)90087-6","article-title":"Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment","volume":"269","author":"Kuoppamaki","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113979_b0355","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/S0022-3565(25)10140-7","article-title":"Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol","volume":"264","author":"Kuoppamaki","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:15:31Z","timestamp":1757769331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220302070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":71,"alternative-id":["S0006295220302070"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113979","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113979"}}